Karen Ingraham, MS

Investigator
GlaxoSmithKline

Disclosure: GlaxoSmithKline (Employee, Shareholder)

I have a B.S. in Genetic Engineering from Cedar Crest College, Allentown, PA and a M.S. in Molecular Biology from Lehigh University, Bethlehem, PA. I have worked at GSK for 23 years in infectious disease. My experience is with early discovery antibacterial programs. Currently, I am working on mechasnisms of resistance (MOR) and mechanisms of action (MOA) studies for the gepotidacin clinical microbiology team.

Poster(s):

1249 - Genetic Evidence That Gepotidacin Shows Well-balanced Dual Targeting against DNA Gyrase And Topoisomerase IV in Neisseria gonorrhoeae
1438 - Dissecting the Multifaceted Nature of Antibiotic Resistance in Clinical Isolates of Neisseria gonorrhoeae by Natural Transformation
1440 - The Genetic Basis for a Neisseria gonorrhoeae Clinical Isolate That Contains mtrR_-79 Mutation But Is Highly Susceptible to Antibiotics Effluxed by the Mtr Pump System